Donor leucocyte infusions
| Patient no. . | Indication . | DLI dose3-150 (mo after transplantation) . | Response . | GVHD . |
|---|---|---|---|---|
| 12 | Persistent disease/ mixed chimerism | 1 (7+) 3 (14+) | > 50% response/ full donor chimerism | II |
| 16 | Immune reconstitution | 1 (8+) | Increase in CD4+ T-cells | 0 |
| 17 | Mixed chimerism | 1 (9+) | Full donor chimerism | I |
| 18 | Persistent disease | 1 (6+) | > 50% response | 0 |
| 3 (9+) | ||||
| 10 (12+) | ||||
| 20 | Progression | 10 (5+) | No response | III |
| 37 | Persistent disease | 1 (6+) | NE | II |
| Patient no. . | Indication . | DLI dose3-150 (mo after transplantation) . | Response . | GVHD . |
|---|---|---|---|---|
| 12 | Persistent disease/ mixed chimerism | 1 (7+) 3 (14+) | > 50% response/ full donor chimerism | II |
| 16 | Immune reconstitution | 1 (8+) | Increase in CD4+ T-cells | 0 |
| 17 | Mixed chimerism | 1 (9+) | Full donor chimerism | I |
| 18 | Persistent disease | 1 (6+) | > 50% response | 0 |
| 3 (9+) | ||||
| 10 (12+) | ||||
| 20 | Progression | 10 (5+) | No response | III |
| 37 | Persistent disease | 1 (6+) | NE | II |
NE indicates not evaluated.
CD3+ T-cell dose administered × 106/kg.